Panel discussion on new drugs in the pipeline for tuberculosis treatment

ERS/UNITE4TB Webinar

3 April, 2025 | Online

13:00-14:00 CET

Chairs: Prof. Dr Raquel Duarte (Porto, Portugal), Prof. Dr Christoph Lange (Borstel, Germany)

Speaker: Prof. Dr Michael Hoelscher (Munich, Germany)

Discussants: Dr Marion Holzapfel (Lyon, France), Dr Abdullah Alsultan (Riyadh, Saudi Arabia)

Fees: Free for ERS members and non-members

Tuberculosis (TB) continues to be a significant global health threat. The use of antibiotics in the treatment of millions of TB patients per year will inevitably lead to the development of resistant strains, presenting a considerable challenge to treatment success. Resistance development can be minimised by optimising regimens (e.g combination of drugs, the right doses, etc.) improving patient adherence, etc.

However, there is a need to constantly develop novel anti-tuberculosis drugs and integrate them into novel regimens. This process is very complex, expensive and time consuming and requires the interplay between many partners. Several new compounds are presently in the clinical pipeline, promising shorter, safer, and more effective treatment regimens. However, their integration into standard clinical practice necessitates a comprehensive understanding of their mechanisms of action, efficacy, safety profiles, and potential interactions. This webinar will offer an update on the latest advancements in TB drug development.

• Overview of current TB treatment challenges and drug resistance
• New and emerging TB drugs in the pipeline
• Clinical trial updates
• Considerations for integrating new drugs into treatment regimens
• Future directions and research gaps

One-hour webinar format: 45 minutes for presentation, followed by a 15-minute Q&A session.

Following this webinar, participants will be able to:

• Identify the key new drugs in development for TB treatment
• Evaluate the clinical trial evidence supporting their efficacy and safety
• Understand potential challenges in implementing new regimens
• Discuss how these drugs can fit into current TB treatment guidelines
• Apply new knowledge to improve patient outcomes and TB control strategies